Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients suffering from stable, persistent, mild to moderate asthma as defined by Global Initiative for Asthma (GINA) Guidelines and for whom FEV1 \> 60 %
ICS taking ≤ 1000 μg BDP per day, or equivalent
Methacholine PC20 \< 4 mg/mL
You may not be if
Known or suspected hypersensitivity to budesonide or any other constituents of the budesonide HFA pMDI or budesonide CFC pMDI.
Currently a smoker or who has ceased smoking within 6 months of Visit 1.
Exacerbations of asthma requiring oral steroids, hospitalisation or change in asthma therapy in the previous three months.
Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or bronchiectasis
Clareo Health | Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma
